Skip to main content

Newsroom

Latest News

February 7, 2019

The Health and Human Services official responsible for helping to reunite families separated by the Trump administration said Thursday he had warned colleagues that separating children from their parents would cause lasting, serious psychological trauma.

February 7, 2019

Colorado U.S. Rep. Diana DeGette oversaw a congressional hearing Thursday on a Trump administration immigration policy that separated thousands of migrant children from their parents if they entered the United States illegally.

DeGette called the policy "cruel" and said the hearing by the House Energy and Commerce oversight subcommittee was intended "to make sure it never happens again."

"These are real kids, real families, that were forcibly torn apart," DeGette, a Denver Democrat, said in her role as the new chairperson of the oversight subcommittee.

February 5, 2019

A House panel is requesting additional documents from the Department of Health and Human Services related to the administration's "zero tolerance" immigration policy that led to the separation of families apprehended along the southern border, after an earlier request went unfulfilled.

February 5, 2019

Washington, DCU.S. Rep. Diana DeGette (D-CO) released the following statement on the president's State of the Union speech this evening:

"What we heard tonight was classic state-of-the-union Trump, who tells everybody what they want to hear. Unfortunately, what we are forced to live with every other day is a president whose actions are doing real harm to our country – from shutting down the government, to ripping families apart at the border, to making it harder for women to get the family planning services they need.

February 4, 2019

Washington, DC U.S. Rep. Diana DeGette (D-CO), chair of the House oversight panel investigating the Trump administration's child-separation policy, today announced the full list of witnesses set to testify this week at the committee's first oversight hearing on the administration's controversial policy.

The hearing, scheduled to take place Thursday, Feb 7, at 10:30am EST in room 2123 of the Rayburn House Office Building, will be DeGette's first as chair of the House Energy and Commerce Committee's Oversight and Investigations panel.

February 4, 2019

This week the Trump administration learns what Democratic oversight looks like.

After a 35-day government shutdown that consumed congressional leaders, Democrats hold a series of hearings this week that define a new normal in Washington: the Trump administration is in the hot seat. Empowered with their new majority and already facing roadblocks from key players in Trump's orbit, committee leaders are moving ahead with the spotlight on some of the President's most controversial policies and associates in a marathon not expected to end for the next two years.

February 1, 2019
It’s been one week since the longest government shutdown in our nation’s history ended, but its effects are still being felt. In fact, the nonpartisan Congressional Budget Office found that President Trump’s decision to shut down our government permanently cost our economy $3 billion.
January 31, 2019

Washington, DC. – The chairman of the House oversight panel investigating the Trump administration's child-separation policy, U.S. Rep. Diana DeGette (D-CO), announced today that her committee will hold its first hearing on the administration's controversial policy one week from today.

The announcement comes just one day before the U.S. Dept. of Health and Human Services is due to turn over dozens of internal documents to DeGette's committee as part of its ongoing investigation of the administration's actions.

January 30, 2019

Washington, DC – Two of the top Democrats on the House Energy and Commerce Committee joined forces today in calling on the heads of three major U.S. pharmaceutical companies to explain the recent skyrocketing cost of insulin.

U.S. Reps. Diana DeGette (D-CO) and Frank Pallone, Jr. (D-NJ) sent letters to the heads of Eli Lilly, Novo Nordisk and Sanofi – three of the top manufactures of insulin in the U.S. – asking them to explain the rapidly increasing cost drug; and why they are not providing a more affordable treatment to patients in need.

January 30, 2019

Two powerful U.S. lawmakers sent letters to the three leading insulin manufacturers on Wednesday requesting information on why its cost has skyrocketed in recent years and how much the companies profit from the life-sustaining diabetes treatment.